玻璃体腔注射雷珠单抗治疗与全视网膜光凝治疗增殖性糖尿病视网膜病变的五年成本效益:一项随机临床试验的二次分析
该研究是对DRCR Retina Network Protocol S随机临床试验的预计划二次分析,纳入213名增殖性糖尿病视网膜病变(PDR)成人患者,比较玻璃体腔注射雷珠单抗0.5 mg与全视网膜光凝(PRP)的5年成本效益并模拟至10年。结果显示,基线无中心受累糖尿病黄斑水肿(CI-DME)者,雷珠单抗组相比PRP的增量成本效益比(ICER)为5年每质量调整生命年(QALY)582 268美元、10年742 202美元/QALY;基线有CI-DME者分别为5年65 576美元/QALY和10年63 930美元/QALY。作者认为,对于PDR伴视力损害性CI-DME的眼,雷珠单抗可能处于美国常引用的成本效益范围内,而对于无视力损害性CI-DME的PDR眼则不在该范围内。
要点
- 基线无CI-DME者,雷珠单抗组相比PRP组的ICER为5年582 268美元/QALY、10年742 202美元/QALY。
- 基线有CI-DME者,雷珠单抗组相比PRP组的ICER为5年65 576美元/QALY、10年63 930美元/QALY。
- 作者认为,抗血管内皮生长因子费用大幅降低可使无基线CI-DME患者也进入成本效益范围。
核心结论
- 本研究提示,在5至10年治疗期间,按试验方案给予雷珠单抗0.5 mg相比PRP,对于就诊时PDR伴视力损害性CI-DME的眼可能处于美国常引用的成本效益范围内,但对于PDR无视力损害性CI-DME的眼则不在该范围内。
- 抗血管内皮生长因子费用大幅降低可能使雷珠单抗治疗即使对无基线CI-DME的患者也进入该成本效益范围。
研究设计与样本
- 本研究是对Protocol S随机临床试验的预计划二次分析,使用5年随访的疗效、安全性和资源利用数据,并模拟至10年。
- 研究纳入213名诊断为PDR的成人,平均(SD)年龄53(12)岁,其中92名(43%)为女性,155名(73%)为白人。
主要发现
- 基线无CI-DME的患者中,雷珠单抗组相比PRP组的ICER为5年582 268美元/QALY,10年742 202美元/QALY。
- 基线有CI-DME的患者中,雷珠单抗组相比PRP组的ICER为5年65 576美元/QALY,10年63 930美元/QALY。
关键数值与推荐
- 基线无CI-DME者:雷珠单抗组相比PRP组的ICER为5年582 268美元/QALY、10年742 202美元/QALY。
- 基线有CI-DME者:雷珠单抗组相比PRP组的ICER为5年65 576美元/QALY、10年63 930美元/QALY。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The DRCR Retina Network Protocol S randomized clinical trial suggested that the mean visual acuity of eyes with proliferative diabetic retinopathy (PDR) treated with ranibizumab is not worse at 5 years than that of eyes treated with panretinal photocoagulation (PRP). Moreover, the ranibizumab group had fewer new cases of diabetic macular edema (DME) with vision loss or vitrectomy but had 4 times the number of injections and 3 times the number of visits. Although 2-year cost-effectiveness results of Protocol S were previously identified, incorporating 5-year data from Protocol S could alter the longer-term cost-effectiveness of the treatment strategies from the perspective of the health care system. OBJECTIVE: To evaluate 5- and 10-year cost-effectiveness of therapy with ranibizumab, 0.5 mg, compared with PRP for treating PDR. DESIGN, SETTING, AND PARTICIPANTS: A preplanned secondary analysis of the Protocol S randomized clinical trial using efficacy, safety, and resource utilization data through 5 years of follow-up for 213 adults diagnosed with PDR and simulating results through 10 years. INTERVENTIONS: Intravitreous ranibizumab, 0.5 mg, at baseline and as frequently as every 4 weeks based on a structured retreatment protocol vs PRP at baseline for PDR; eyes in both groups could receive ranibizumab for concomitant DME with vision loss. MAIN OUTCOMES AND MEASURES: Incremental cost-effectiveness ratios (ICERs) of ranibizumab therapy compared with PRP were evaluated for those with and without center-involved DME (CI-DME) and vision loss (Snellen equivalent, 20/32 or worse) at baseline. RESULTS: The study included 213 adults with a mean (SD) age of 53 (12) years, of whom 92 (43%) were women and 155 (73%) were white. The ICER of the ranibizumab group compared with PRP for patients without CI-DME at baseline was $582 268 per quality-adjusted life-year (QALY) at 5 years and $742 202/QALY at 10 years. For patients with baseline CI-DME, ICERs were $65 576/QALY at 5 years and $63 930/QALY at 10 years. CONCLUSIONS AND RELEVANCE: This study suggests that during 5 to 10 years of treatment, ranibizumab, 0.5 mg, as given in the studied trial compared with PRP may be within the frequently cited range considered cost-effective in the United States for eyes presenting with PDR and vision-impairing CI-DME, but not for those with PDR but without vision-impairing CI-DME. Substantial reductions in anti-vascular endothelial growth factor cost may make the ranibizumab therapy cost-effective within this range even for patients without baseline CI-DME. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01489189.
引用
- Hutton DW, Stein JD, Glassman AR, et al. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2019. PMID: 31647496. doi:10.1001/jamaophthalmol.2019.4284
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。